Cargando…

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic myeloid leukemia patients. Achieving a sustained deep molecular response (DMR) before stop is recommended. Currently, the proportion of patients who achieve a sustained DMR remains to be determined. Based on the f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Etienne, Gabriel, Dulucq, Stéphanie, Bauduer, Fréderic, Adiko, Didier, Lifermann, François, Dagada, Corinne, Lenoir, Caroline, Schmitt, Anna, Klein, Emilie, Madene, Samia, Fort, Marie-Pierre, Bijou, Fontanet, Moldovan, Marius, Turcq, Beatrice, Robbesyn, Fanny, Durrieu, Françoise, Versmée, Laura, Katsahian, Sandrine, Faberes, Carole, Lascaux, Axelle, Mahon, François-Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565328/ https://www.ncbi.nlm.nih.gov/pubmed/32899879 http://dx.doi.org/10.3390/cancers12092521

Ejemplares similares

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2021)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Treatment-Free Remission: the New Goal in CML Therapy
por: Atallah, Ehab, et al.
Publicado: (2021)

Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
por: Dulucq, Stéphanie, et al.
Publicado: (2016)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2011)

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
por: Dulucq, Stephanie, et al.
Publicado: (2022)

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
por: Jacobi, Henrike, et al.
Publicado: (2023)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
por: Dumas, Pierre‐Yves, et al.
Publicado: (2019)

Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
por: Trinh, Anne, et al.
Publicado: (2021)

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients
por: Matsushita, M, et al.
Publicado: (2017)

Treatment-free remission: A new goal for all chronic phase (CP)-CML patients
por: Rea, Delphine
Publicado: (2018)

The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
por: Patterson, Shaun David, et al.
Publicado: (2023)

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
por: Saussele, Susanne, et al.
Publicado: (2018)

Novel analytical methods to interpret large sequencing data from small sample sizes
por: Lichou, Florence, et al.
Publicado: (2019)

Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells
por: Latour, Simon, et al.
Publicado: (2019)

Cytogenetic study in CML
por: Subramanian, P.G.
Publicado: (2012)

CML: Evolution and design
por: Murray-Rust, Peter, et al.
Publicado: (2011)

A folate receptor 3 SNP promotes mitochondria‐induced clonogenicity of CML leukemia cells: Implications for treatment free remission
por: Shen, Na, et al.
Publicado: (2021)

Choline PET/CT in Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2020)

Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation
por: Bedel, Aurélie, et al.
Publicado: (2013)

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Eradication of CML stem cells
por: Carter, Bing Z., et al.
Publicado: (2016)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
por: Zhou, Lu, et al.
Publicado: (2019)

Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant
por: Mesguich, Charles, et al.
Publicado: (2021)

La pandémie de COVID-19 : retour vers le futur ou le combat sans fin entre l’Homme et les microbes
por: Bauduer, Frédéric
Publicado: (2020)

CMLLite: a design philosophy for CML
por: Townsend, Joe A, et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

The New ELN Recommendations for Treating CML
por: Hehlmann, Rüdiger
Publicado: (2020)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
por: Hamza, Marwa S, et al.
Publicado: (2022)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
por: Pavlovsky, Carolina, et al.
Publicado: (2023)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
por: Muselli, Fabien, et al.
Publicado: (2021)

Social Networks in French Balneotherapy: A Focus on Spa Doctors
por: Ramon Dupuy, Sybille, et al.
Publicado: (2023)

Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019
por: Montastruc, François, et al.
Publicado: (2020)

On the Power of Additional and Complex Chromosomal Aberrations in CML
por: Greulich-Bode, Karin M, et al.
Publicado: (2012)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Cobll1: A new player in CML
por: Kim, Hongtae, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3s4p0ibpg213hvakpdpttuva6k